KOREA PHARMA's 'Star Ruckus' Listed on Non-Covered List, Expanding Access to Pediatric ADHD Prescriptions
- Input
- 2026-09-29 11:54:11
- Updated
- 2026-09-29 11:54:11

[Financial News] KOREA PHARMA's pediatric attention-deficit/hyperactivity disorder (ADHD) digital therapeutic device, 'Star Ruckus,' has been added to the non-covered list, laying the groundwork for expanded prescribing in clinical settings.
KOREA PHARMA announced on the 29th that Star Ruckus had been added to the Ministry of Health and Welfare (MOHW)'s non-covered list for digital therapeutic devices classified as innovative medical technologies and had been assigned code 'TX014.'
The listed item is 'cognitive multitasking training for pediatric patients with attention-deficit/hyperactivity disorder using a digital therapeutic device.' The listing clarifies the code and fee standards applied when medical institutions prescribe Star Ruckus, which is expected to improve healthcare professionals' access to prescribing it.
Star Ruckus is a game-based digital therapeutic device developed to treat ADHD in children. Under the prescription of a healthcare professional, children diagnosed with ADHD undergo personalized cognitive training through a mobile application for four weeks.
KOREA PHARMA has been strengthening its mental health treatment portfolio since signing an agreement last November with eMotiv, a developer of digital therapeutic devices, to introduce Star Ruckus in South Korea and sell it exclusively. More recently, the device was featured on the parenting program 'My Golden Kids' as a digital therapeutic device that provides concentration training during the treatment of a child with ADHD. Its prescription base in clinical settings has also expanded since its launch. More than 130 medical institutions have registered as institutions authorized to implement Star Ruckus as an innovative medical technology.
A KOREA PHARMA official said, "A foundation has been laid for the more systematic use of Star Ruckus in clinical settings." The official added, "Based on the network of medical institutions we have established in the central nervous system (CNS) field, we will continue to provide integrated mental health solutions optimized for pediatric patients and their guardians, expand the number of prescribing institutions, and further improve patient access."
[email protected] Choi Doo-sun Reporter